RodrÃguez-Fernández, K.; Mangas-Sanjuán, V.; Merino-Sanjuán, M.; Martorell-Calatayud, A.; Mateu-Puchades, A.; Climente-MartÃ, M.; Gras-Colomer, E.
Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. Pharmaceutics 2022, 14, 654.
https://doi.org/10.3390/pharmaceutics14030654
AMA Style
RodrÃguez-Fernández K, Mangas-Sanjuán V, Merino-Sanjuán M, Martorell-Calatayud A, Mateu-Puchades A, Climente-Martà M, Gras-Colomer E.
Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. Pharmaceutics. 2022; 14(3):654.
https://doi.org/10.3390/pharmaceutics14030654
Chicago/Turabian Style
RodrÃguez-Fernández, Karine, VÃctor Mangas-Sanjuán, Matilde Merino-Sanjuán, Antonio Martorell-Calatayud, Almudena Mateu-Puchades, Mónica Climente-MartÃ, and Elena Gras-Colomer.
2022. "Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis" Pharmaceutics 14, no. 3: 654.
https://doi.org/10.3390/pharmaceutics14030654
APA Style
RodrÃguez-Fernández, K., Mangas-Sanjuán, V., Merino-Sanjuán, M., Martorell-Calatayud, A., Mateu-Puchades, A., Climente-MartÃ, M., & Gras-Colomer, E.
(2022). Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. Pharmaceutics, 14(3), 654.
https://doi.org/10.3390/pharmaceutics14030654
